PHASE 1 TRIAL OF G-CSF, CLADRIBINE, CYTARABINE, AND DOSE-ESCALATED MITOXANTRONE (G-CLAM) IN ADULTS WITH NEWLY DIAGNOSED AML OR HIGH-RISK MDS

被引：0
|
作者：
Anwar, A. [1 ]
Halpern, A. [1 ]
Scott, B. [1 ]
Becker, P. [1 ]
Othus, M. [1 ]
Hendrie, P. [2 ]
Ranker, E. [3 ]
Perdue, A. [3 ]
Chen, T. [2 ]
Buckley, S. [1 ]
Orlowski, K. [1 ]
Powell, M. [1 ]
Appelbaum, F. [1 ]
Estey, E. [1 ]
Walter, R. [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Seattle Canc Care Alliance, Seattle, WA USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P574
引用
收藏
页码：219 / 219
页数：1
相关论文
共 50 条
  • [1] A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Smith, Heather A.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Perdue, Andrea M.
    Chen, Tara L.
    Buckley, Sarah A.
    Erba, Harry P.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [2] Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
    Anwar, Asma
    Halpern, Anna B.
    Othus, Megan
    Scott, Bart L.
    Hendrie, Paul C.
    Becker, Pamela S.
    Perdue, Andrea M.
    Smith, Heather A.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2015, 126 (23)
  • [3] Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
    Godwin, Colin D.
    Othus, Megan
    Percival, Mary-Elizabeth M.
    Scott, Bart L.
    Becker, Pamela S.
    Gardner, Kelda M.
    Keel, Sioban B.
    Dhawale, Tejaswini M.
    Oehler, Vivian G.
    Abkowitz, Janis L.
    Halpern, Anna B.
    Hendrie, Paul C.
    Orlowski, Kaysey F.
    Woo, Alice
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2019, 134
  • [4] A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
    Godwin, Colin D.
    Othus, Megan
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Scott, Bart L.
    Appelbaum, Jacob S.
    Halpern, Anna B.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Keel, Sioban B.
    Abkowitz, Janis L.
    Cooper, Jason P.
    Cassaday, Ryan D.
    Orlowski, Kaysey F.
    Marshall, Anise J.
    Brown, Clarisa N.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2021, 138
  • [5] G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial
    Halpern, Anna B.
    Huebner, Emily M.
    Othus, Megan
    Scott, Bart L.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Gardner, Kelda M.
    Buckley, Sarah A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2017, 130
  • [6] Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
    Halpern, Anna B.
    Rodriguez-Arboli, Eduardo
    Othus, Megan
    Garcia, Kelsey-Leigh A.
    Percival, Mary-Elizabeth M.
    Cassaday, Ryan D.
    Oehler, Vivian G.
    Becker, Pamela S.
    Appelbaum, Jacob S.
    Abkowitz, Janis L.
    Orozco, Johnnie J.
    Keel, Sioban B.
    Hendrie, Paul C.
    Scott, Bart L.
    Ghiuzeli, M. Cristina
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD ADVANCES, 2023, 7 (17) : 4950 - 4961
  • [7] Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Becker, Pamela S.
    Smith, Heather A.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Cassaday, Ryan D.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Estey, Elihu H.
    Walter, Roland B.
    HAEMATOLOGICA, 2019, 104 (04) : E143 - E146
  • [8] Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Appelbaum, Frederick R.
    Erba, Harry P.
    Estey, Elihu H.
    Walter, Roland B.
    LEUKEMIA, 2018, 32 (11) : 2352 - 2362
  • [9] Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
    Anna B. Halpern
    Megan Othus
    Emily M. Huebner
    Bart L. Scott
    Pamela S. Becker
    Mary-Elizabeth M. Percival
    Paul C. Hendrie
    Kelda M. Gardner
    Tara L. Chen
    Sarah A. Buckley
    Kaysey F. Orlowski
    Asma Anwar
    Frederick R. Appelbaum
    Harry P. Erba
    Elihu H. Estey
    Roland B. Walter
    Leukemia, 2018, 32 : 2352 - 2362
  • [10] Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid Neoplasms
    Raychaudhuri, Suravi
    Gooley, Ted
    Gill, Zach
    Rasmussen, Allegra
    Halpern, Anna B.
    Appelbaum, Jacob S.
    Ghiuzeli, Cristina Maria
    Hendrie, Paul C.
    Cassaday, Ryan D.
    Walter, Roland B.
    Estey, Elihu
    Percival, Mary-Elizabeth M.
    BLOOD, 2023, 142
12345